XSTO
CRADb
Market cap116mUSD
Jun 05, Last price
34.05SEK
1D
2.25%
1Q
10.19%
Jan 2017
182.57%
IPO
78.27%
Name
C Rad AB
Chart & Performance
Profile
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||||
Revenues | 469,000 10.45% | 424,615 40.92% | 301,326 15.38% | |||||||
Cost of revenue | 146,000 | 141,653 | 100,547 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 323,000 | 282,962 | 200,779 | |||||||
NOPBT Margin | 68.87% | 66.64% | 66.63% | |||||||
Operating Taxes | 23,300 | 8,397 | 14,006 | |||||||
Tax Rate | 7.21% | 2.97% | 6.98% | |||||||
NOPAT | 299,700 | 274,565 | 186,773 | |||||||
Net income | 56,500 59.03% | 35,529 375.05% | 7,479 -70.21% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (3,800) | (2,292) | 1,004 | |||||||
BB yield | 0.37% | 0.16% | -0.08% | |||||||
Debt | ||||||||||
Debt current | (18,973) | |||||||||
Long-term debt | 18,000 | 3,506 | 8,152 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | (1,000) | |||||||||
Net debt | (132,900) | (125,855) | (143,033) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 29,900 | 33,383 | 9,690 | |||||||
CAPEX | (4,106) | (11,222) | ||||||||
Cash from investing activities | (6,500) | (16,931) | (11,222) | |||||||
Cash from financing activities | (7,100) | (5,690) | (2,384) | |||||||
FCF | 257,055 | 245,117 | 173,330 | |||||||
Balance | ||||||||||
Cash | 150,900 | 129,361 | 121,896 | |||||||
Long term investments | 10,316 | |||||||||
Excess cash | 127,450 | 108,130 | 117,146 | |||||||
Stockholders' equity | (105,034) | (138,914) | ||||||||
Invested Capital | 334,000 | 377,967 | 366,560 | |||||||
ROIC | 84.19% | 73.76% | 50.66% | |||||||
ROCE | 95.93% | 103.67% | 88.20% | |||||||
EV | ||||||||||
Common stock shares outstanding | 33,832 | 33,767 | 33,764 | |||||||
Price | 30.00 -28.91% | 42.20 10.76% | 38.10 -31.60% | |||||||
Market cap | 1,014,970 -28.77% | 1,424,965 10.77% | 1,286,409 -31.94% | |||||||
EV | 882,070 | 1,299,110 | 1,143,376 | |||||||
EBITDA | 323,000 | 291,823 | 210,891 | |||||||
EV/EBITDA | 2.73 | 4.45 | 5.42 | |||||||
Interest | 379 | 416 | ||||||||
Interest/NOPBT | 0.13% | 0.21% |